"Challenging market" shrinks BioHeart IPO size
This article was originally published in Clinica
Just over a year after filing for an IPO, cardiovascular cell-based therapy specialist BioHeart has ended a drawn out gestation period by listing on the Nasdaq Stock Exchange. However, the company cut the number of shares it had intended to float and saw a 65% mark-down on its opening share price when it debuted on February 19.
You may also be interested in...
Hours before the US FDA confirmed the first drug shortage due to active pharmaceutical ingredient constraints because of the coronavirus situation in China, generics industry leader Mylan came under pressure about the potential impact on its business.
Government advisory committee gives initial nod to what will become Japan’s most expensive single drug, but reimbursement pricing could come in for close scrutiny.
Laparoscopic power morcellation to remove uterine fibroids should only be performed with the use of a compatible containment system, and only on women younger than 50, the US FDA said in a newly published safety communication and draft guidance document. See what the president of the gynecologic trade group AAGL, Jubilee Brown, said about it here.